Refractory Clinical Trials in Hefei, Anhui
14 recruitingHefei, Anhui, China
Showing 1–14 of 14 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Not Applicable
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
Anhui Provincial Hospital12 enrolled1 locationNCT06321198
Recruiting
Not Applicable
KD Treatment for Super-refractory Status Epilepticus
Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing84 enrolled15 locationsNCT07496749
Recruiting
Phase 1
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
Systemic Lupus Erythematosus (SLE)Refractory
Chongqing Precision Biotech Co., Ltd12 enrolled2 locationsNCT06892145
Recruiting
Early Phase 1
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.36 enrolled5 locationsNCT07095075
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 1
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University30 enrolled6 locationsNCT07002112
Recruiting
Phase 2
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China41 enrolled3 locationsNCT06224257
Recruiting
Early Phase 1
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
CD19-positive Relapsed or Refractory B-cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.10 enrolled1 locationNCT06092047
Recruiting
Phase 1
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-Cell Non-Hodgkin Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-Refractory
Tianjin Medical University Cancer Institute and Hospital33 enrolled2 locationsNCT06395870
Recruiting
Phase 2
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Relapse/RecurrenceAML, ChildhoodRefractory AML+2 more
Children's Hospital of Soochow University50 enrolled12 locationsNCT06316960
Recruiting
Phase 1
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
The First Affiliated Hospital with Nanjing Medical University10 enrolled1 locationNCT06503211
Recruiting
Not Applicable
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy
Refractory EpilepsyTranscranial Direct Current StimulationFunctional Magnetic Resonance Imaging+2 more
Anhui Medical University90 enrolled1 locationNCT06241963